167 related articles for article (PubMed ID: 36029108)
1. Population Pharmacokinetics and Hemorrhagic Risk Analysis of Rivaroxaban in Elderly Chinese Patients With Nonvalvular Atrial Fibrillation.
Zhang D; Chen W; Qin W; Du W; Wang X; Zuo X; Li P
J Clin Pharmacol; 2023 Jan; 63(1):66-76. PubMed ID: 36029108
[TBL] [Abstract][Full Text] [Related]
2. Population pharmacokinetic and pharmacodynamic analysis of rivaroxaban in Chinese patients with non-valvular atrial fibrillation.
Liu XQ; Zhang YF; Ding HY; Yan MM; Jiao Z; Zhong MK; Ma CL
Acta Pharmacol Sin; 2022 Oct; 43(10):2723-2734. PubMed ID: 35354961
[TBL] [Abstract][Full Text] [Related]
3. Population Pharmacokinetics of Rivaroxaban in Chinese Patients with Non-Valvular Atrial Fibrillation: A Prospective Multicenter Study.
Zhang F; Chen X; Wu T; Huang N; Li L; Yuan D; Xiang J; Wang N; Chen W; Zhang J
Clin Pharmacokinet; 2022 Jun; 61(6):881-893. PubMed ID: 35316848
[TBL] [Abstract][Full Text] [Related]
4. Population pharmacokinetics of rivaroxaban in Chinese deep vein thrombosis patients and the exposure simulation for dosing recommendation.
Li Z; Yang S; Hua Z; Lu Y; Li X
Naunyn Schmiedebergs Arch Pharmacol; 2024 May; 397(5):3351-3362. PubMed ID: 37950768
[TBL] [Abstract][Full Text] [Related]
5. Association of Rivaroxaban vs Apixaban With Major Ischemic or Hemorrhagic Events in Patients With Atrial Fibrillation.
Ray WA; Chung CP; Stein CM; Smalley W; Zimmerman E; Dupont WD; Hung AM; Daugherty JR; Dickson A; Murray KT
JAMA; 2021 Dec; 326(23):2395-2404. PubMed ID: 34932078
[TBL] [Abstract][Full Text] [Related]
6. Thromboembolism, bleeding and vascular death in nonvalvular atrial fibrillation patients with type 2 diabetes receiving rivaroxaban or warfarin.
Coleman CI; Costa OS; Brescia CW; Vardar B; Abdelgawwad K; Sood N
Cardiovasc Diabetol; 2021 Feb; 20(1):52. PubMed ID: 33637082
[TBL] [Abstract][Full Text] [Related]
7. Design and Rationale of the RELAXED (Recurrent Embolism Lessened by rivaroxaban, an Anti-Xa agent, of Early Dosing for acute ischemic stroke and transient ischemic attack with atrial fibrillation) Study.
Yasaka M; Minematsu K; Toyoda K; Yamagami H; Yoshimura S; Nagao T; Mori E; Hirano T; Hamasaki T; Yamaguchi T
J Stroke Cerebrovasc Dis; 2016 Jun; 25(6):1342-8. PubMed ID: 26987488
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF).
Halperin JL; Hankey GJ; Wojdyla DM; Piccini JP; Lokhnygina Y; Patel MR; Breithardt G; Singer DE; Becker RC; Hacke W; Paolini JF; Nessel CC; Mahaffey KW; Califf RM; Fox KA;
Circulation; 2014 Jul; 130(2):138-46. PubMed ID: 24895454
[TBL] [Abstract][Full Text] [Related]
9. CHA
Peacock WF; Tamayo S; Patel M; Sicignano N; Hopf KP; Yuan Z
Ann Emerg Med; 2017 May; 69(5):541-550.e1. PubMed ID: 27913059
[TBL] [Abstract][Full Text] [Related]
10. How to handle the delayed or missed dose of rivaroxaban in patients with non-valvular atrial fibrillation: model-informed remedial dosing.
Liu XQ; Yin YW; Wang CY; Li ZR; Zhu X; Jiao Z
Expert Rev Clin Pharmacol; 2021 Sep; 14(9):1153-1163. PubMed ID: 34058934
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Frail Patients With Nonvalvular Atrial Fibrillation.
Martinez BK; Sood NA; Bunz TJ; Coleman CI
J Am Heart Assoc; 2018 Apr; 7(8):. PubMed ID: 29654196
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study.
Maura G; Blotière PO; Bouillon K; Billionnet C; Ricordeau P; Alla F; Zureik M
Circulation; 2015 Sep; 132(13):1252-60. PubMed ID: 26199338
[TBL] [Abstract][Full Text] [Related]
13. Characteristics, Management, and Outcomes of Patients with Atrial Fibrillation Experiencing a Major Bleeding Event While on Rivaroxaban.
Burgos KD; Sienko SE; Hoffman JL; Koerber JM; Smythe MA
Clin Appl Thromb Hemost; 2018 Mar; 24(2):372-378. PubMed ID: 28301906
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness and Safety of Four Direct Oral Anticoagulants in Asian Patients With Nonvalvular Atrial Fibrillation.
Chan YH; Lee HF; See LC; Tu HT; Chao TF; Yeh YH; Wu LS; Kuo CT; Chang SH; Lip GYH
Chest; 2019 Sep; 156(3):529-543. PubMed ID: 31103697
[TBL] [Abstract][Full Text] [Related]
15. Comparative Safety and Effectiveness of Oral Anticoagulants in Nonvalvular Atrial Fibrillation: The NAXOS Study.
Van Ganse E; Danchin N; Mahé I; Hanon O; Jacoud F; Nolin M; Dalon F; Lefevre C; Cotté FE; Gollety S; Falissard B; Belhassen M; Steg PG
Stroke; 2020 Jul; 51(7):2066-2075. PubMed ID: 32539675
[TBL] [Abstract][Full Text] [Related]
16. Comparisons of Rivaroxaban Following Different Dosage Criteria (ROCKET AF or J-ROCKET AF Trials) in Asian Patients With Atrial Fibrillation.
Chan YH; Lee HF; Wang CL; Chang SH; Yeh CH; Chao TF; Yeh YH; Chen SA; Kuo CT
J Am Heart Assoc; 2019 Nov; 8(21):e013053. PubMed ID: 31623498
[TBL] [Abstract][Full Text] [Related]
17. Clinical Risk Factors of Thromboembolic and Major Bleeding Events for Patients with Atrial Fibrillation Treated with Rivaroxaban in Japan.
Miyamoto S; Ikeda T; Ogawa S; Kitazono T; Nakagawara J; Minematsu K; Murakawa Y; Iwashiro S; Takeichi M; Kidani Y; Okayama Y; Sunaya T; Sato S; Yamanaka S
J Stroke Cerebrovasc Dis; 2020 Apr; 29(4):104584. PubMed ID: 31983518
[TBL] [Abstract][Full Text] [Related]
18. Monitoring of anti-Xa activity and factors related to bleeding events: A study in Japanese patients with nonvalvular atrial fibrillation receiving rivaroxaban.
Sakaguchi T; Osanai H; Murase Y; Ishii H; Nakashima Y; Asano H; Suzuki S; Takefuji M; Inden Y; Sakai K; Murohara T; Ajioka M
J Cardiol; 2017 Sep; 70(3):244-249. PubMed ID: 28017463
[TBL] [Abstract][Full Text] [Related]
19. Characteristics and outcomes in patients with atrial fibrillation receiving direct oral anticoagulants in off-label doses.
Briasoulis A; Gao Y; Inampudi C; Alvarez P; Asleh R; Chrischilles E; Leira EC; Vaughan-Sarrazin M
BMC Cardiovasc Disord; 2020 Feb; 20(1):42. PubMed ID: 32013886
[TBL] [Abstract][Full Text] [Related]
20. Thromboembolic, Bleeding, and Mortality Risks of Rivaroxaban and Dabigatran in Asians With Nonvalvular Atrial Fibrillation.
Chan YH; Kuo CT; Yeh YH; Chang SH; Wu LS; Lee HF; Tu HT; See LC
J Am Coll Cardiol; 2016 Sep; 68(13):1389-1401. PubMed ID: 27659460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
